Dr. Tamaro Hudson is a dedicated cancer biologist and translational research leader focused on developing precision therapies and biomarker-driven approaches for prostate and solid tumor malignancies. At Howard University Cancer Center, his research centers on understanding how bioactive natural compounds and genetic biomarkers can suppress or reverse tumorigenesis, aiming to improve cancer prevention and treatment outcomes. His work integrates molecular pharmacology, epidemiology, and clinical translation, emphasizing pathways relevant to cancer disparities in African American men. As Chief Scientific Officer at OncoVanta Therapeutics, Dr. Hudson leads translational strategy and preclinical program development, guiding efforts to advance mutant p53-targeting TCR-T cell therapies from laboratory validation toward clinical readiness.